EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. - Wikidata - awgldk - TriplyDB

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

http://www.wikidata.org/entity/Q33756853

about

Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Recurrent high-grade glioma: a diagnostic and therapeutic challenge.3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice PTEN reconstitution alters glioma responses to c-Met pathway inhibition.Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.Novel therapies in glioblastoma.Emerging insights into the molecular and cellular basis of glioblastoma.Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth.Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.Dynamic glucose enhanced (DGE) MRI for combined imaging of blood-brain barrier break down and increased blood volume in brain cancer.Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells Microarray-Based Phospho-Proteomic Profiling of Complex Biological Systems.Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells.Emerging antibody combinations in oncology.EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Targeting adaptive glioblastoma: an overview of proliferation and invasion.ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation.Mitochondrial Impairment May Increase Cellular NAD(P)H: Resazurin Oxidoreductase Activity, Perturbing the NAD(P)H-Based Viability Assays.MET gain in diffuse astrocytomas is associated with poorer outcome.EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers.Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance.

P2860

Q26852366-299F23EE-AF6E-48ED-8AF0-BA25EDDAB175 Q27011423-FA5864AA-0CE1-4D9B-A379-7A87073A9C4B Q27022941-8E78CC35-5115-4302-A596-47F53C1F421E Q30427677-4FF7FF61-9888-49C2-BE00-F248E2F794FB Q30456087-1F62663F-ABF2-4B14-9634-77C3F52DC3E0 Q33864058-6B84653D-6193-4107-BCB7-BB9C6A2798A7 Q33937876-99D76C91-965A-4043-A09E-34F7A513646A Q34043232-0F0E45FB-96BB-45C5-813E-6212818C6648 Q34627751-3F93CCE9-F5A1-438A-9EB1-2A600B912660 Q35188319-5B7EE744-2B6C-4385-8809-208DF1BA48A0 Q35673676-0F29F897-4715-44DC-A3D9-26B2C2447F0F Q35864136-A2488F5B-019A-491D-BD9C-7C25E260D1FA Q35914897-D8815265-9696-43DD-920E-E34001BEA678 Q36062996-A3BA3F04-A297-46B4-B56D-FF0A63672129 Q36072027-D46B751F-0A90-43FE-97EC-C266ADFB5E6A Q36470172-BC22AF85-9D93-4B8A-BA94-11CFD7571732 Q36705901-DBDA92D2-4E7C-4179-8E03-6533A49C634F Q36730368-6659294E-AA21-4A28-AD23-2C207B80DFA9 Q36804501-625D6D04-BFAD-4428-8DB3-C2060346A6A2 Q36924414-AE730150-8249-4D8E-B362-CB3D000231F7 Q37470505-CD6E178F-1113-4353-8651-7F92F0F4D0DA Q37688839-D943F36D-9659-4D34-AFDF-F176BB6784B9 Q37893414-DB5BECE5-8696-41CD-A51D-9B5D441D0624 Q38199643-1CE6BD6A-6EE0-4AC4-8779-83D0361709D6 Q38203283-94E63B26-1037-44F6-9F28-D908F5607862 Q38235930-D684A722-E2DB-4E64-8D69-9E0B117C33E4 Q38398440-54C143E7-7FF2-4D35-8DB7-85072E4475FC Q38778367-E82B86D4-32AE-4219-B822-DD34B9DEB34B Q39503071-62F57446-B75A-4A01-A056-12FD8056EB73 Q39509236-F5B99C0C-236C-4FC9-A6D2-8DD222E8D2A5 Q41616449-16A69B27-9AB5-4FC2-9BFF-641D839AB8ED Q45839064-7664296B-EFBB-498D-AEDF-CF006F657812 Q55460776-F9128253-ADA4-4875-AD66-D1E51E505538 Q55462828-82EC9493-70C1-4D45-86A4-041AC85949A8

P2860

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

http://www.wikidata.org/entity/Q33756853

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

EGFRvIII and c-Met pathway inh ...... vIII+ glioblastoma xenografts.

@ast

EGFRvIII and c-Met pathway inh ...... vIII+ glioblastoma xenografts.

@en

type

label

EGFRvIII and c-Met pathway inh ...... vIII+ glioblastoma xenografts.

@ast

EGFRvIII and c-Met pathway inh ...... vIII+ glioblastoma xenografts.

@en

prefLabel

EGFRvIII and c-Met pathway inh ...... vIII+ glioblastoma xenografts.

@ast

EGFRvIII and c-Met pathway inh ...... vIII+ glioblastoma xenografts.

@en

P1433

Q33756853-4532BACE-ABEE-4945-9F11-F1EE8912BF1F

P1476

Q33756853-54B421DB-408B-4911-B410-6FF199B38296

P2093

Q33756853-0FE23ABA-EB9A-445B-929D-F228906EC426

Q33756853-2A84E1C9-0A20-4809-8211-C215FF13D39A

Q33756853-35C13C79-DB81-44B9-AB81-41A0773A8199

Q33756853-41568EAF-5CCF-4DE3-AAC8-51A219F651DB

Q33756853-63C6DFDE-70D9-4512-B94B-C6F5010D386F

Q33756853-BFC607C5-6369-4DC0-95F4-F39FF66FA930

Q33756853-DFBDA23C-6612-43E3-B3DA-B70E6CDD7319

Q33756853-E8B9E8B9-DEF8-41B1-B906-7D5A310EAC40

P2860

Q33756853-05CDF71A-FE59-4887-BBF8-CD32B503657A

Q33756853-087E9CC1-730A-42C7-9CF9-5D8D36BFB0D6

Q33756853-089269F3-AD5A-4D15-840D-9F2215D172A6

Q33756853-0BECC13D-A4CF-445F-B8D2-02FA55842248

Q33756853-2107BDB6-BE86-4490-9BF6-B88617FF44B7

Q33756853-214711C3-7D6E-436D-8EBB-977ED41DF8E7

Q33756853-219BAB6E-D1F3-4689-9E99-2D21EBFA90B8

Q33756853-3866BD43-8EFA-4000-80B6-564D1A363A32

Q33756853-3C25800D-784F-481C-BCBF-EC6E69810CDC

Q33756853-3CE5F161-856F-4FAD-971F-100B016855EF

P304

Q33756853-3A951B8A-03D0-406E-B639-FF313FA33DBD

P31

Q33756853-615A30B9-7CF3-426C-B3C9-CFA08C23B493

P356

Q33756853-58D78BAE-5346-4757-B53C-BB6AE9732AFE

P433

Q33756853-712FAB59-4AC4-4B17-AC31-329D30DCD4DB

P478

Q33756853-885C3304-EB8F-45FD-B057-2EE88959FF62

P50

Q33756853-42AB9A37-3CCC-473B-9007-C953263086C5

P577

Q33756853-6727A924-7B14-4EAB-8C01-9F9AB52D19F5

P698

Q33756853-F34FDD9C-77BA-4F1F-B26A-899DD1B52308

P921

Q33756853-8C00E00A-A76D-479B-81DC-EB1E2AA715D9

P932

Q33756853-77507E4A-4D1D-4823-8B9D-048BF6DA6617

P356

1535-7163.MCT-09-0188

P1433

Molecular Cancer Therapeutics

P1476

EGFRvIII and c-Met pathway inh ...... RvIII+ glioblastoma xenografts

@en

P2093

Bachchu Lal

http://www.w3.org/2001/XMLSchema#string

Catherine A Foss

http://www.w3.org/2001/XMLSchema#string

Jin Kim

http://www.w3.org/2001/XMLSchema#string

John Laterra

http://www.w3.org/2001/XMLSchema#string

Kathrine Cornet

http://www.w3.org/2001/XMLSchema#string

Martin G Pomper

http://www.w3.org/2001/XMLSchema#string

Sameena Muzamil

http://www.w3.org/2001/XMLSchema#string

Yingying Sang

http://www.w3.org/2001/XMLSchema#string

P2860

HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo

Met, metastasis, motility and more

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

P304

1751-1760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-09-0188

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

C. Rory Goodwin

P577

2009-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19584231

http://www.w3.org/2001/XMLSchema#string

P921

P932

2846399

http://www.w3.org/2001/XMLSchema#string